The use of intravitreous antivascular endothelial growth factor to prevent center-involved diabetic macular edema (CI-DME) with vision loss and proliferative diabetic retinopathy (PDR) has been investigated and recently reported in two randomized clinical trials. Although both trials showed substantial superiority of aflibercept at preventing the development of vision-threatening complications (VTCs) of CI-DME or PDR compared with sham at 1 or 2 years, without a concomitant benefit in visual acuity outcomes, the interpretation of the results and its application to clinical practice resulted in two disparate opinions. In this review, we discuss these two trials including their similarities and differences, other relevant studies, and considerations regarding the interpretation and the application of these results into clinical practice.

中文翻译：

---

预防糖尿病视网膜病变中威胁视力的并发症：基于 DRCR 视网膜网络协议 W 和再生元赞助的 PANORAMA 结果的两种观点。

使用玻璃体内抗血管内皮生长因子来预防中心相关的糖尿病性黄斑水肿 (CI-DME) 伴视力丧失和增殖性糖尿病视网膜病变 (PDR) 已得到研究，最近在两项随机临床试验中进行了报道。尽管两项试验均表明，与假手术相比，阿柏西普在预防 CI-DME 或 PDR 的视力威胁并发症 (VTC) 的发展方面在 1 年或 2 年时具有显着优势，但在视力结果方面没有伴随的益处，但对结果的解释和其在临床实践中的应用导致了两种不同的意见。在这篇综述中，我们讨论了这两项试验，包括它们的相似之处和差异、其他相关研究，以及关于这些结果的解释和临床实践应用的考虑因素。